Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Shifts in income, goals, or family needs make change necessary; use this guide to justify and implement thoughtful budget updates.
26,233 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
As AI headlines drive swings in tech stocks, investors ask whether Vanguard's broad tech ETF is the right pick for 20...
Ethereum approaches a decisive breakout, slipping about 4% to the $2,380s. Analysts highlight a binary setup: a drop ...
Nebius Group delivered a blowout Q1 2026, with revenue growth of 684% and a high-stakes push from NVIDIA and Meta, tr...
A health diagnosis that tilted retirement math retools how seniors claim Social Security and invest. This report expl...
Rocket Mortgage and Rocket Pro are rolling out VantageScore 4.0 in the mortgage qualification process, pairing it wit...
Investors are weighing a bold ripple (xrp) price prediction as regulatory chatter and on-chain expansion add fuel to ...
April inflation rose to 3.8% year over year, the hottest in nearly three years, as gas and groceries push costs highe...
The travel sector is retooling pricing and perks as costs rise and consumers push for clarity. Southwest ditched free...
Geopolitical tension in the Middle East sparked a swift crypto reaction, with Bitcoin swinging as officials weigh a p...
Oracle confronts a fresh wave of investor anxiety as a heavy OpenAI backlog, negative cash flow, and mounting leverag...
Goldman Sachs data reveal a rapid major shift as college students voting with AI concerns reshape the 2025-26 academi...